Developers advancing a new slate of weight loss drugs

The Wall Street Journal reviews the slate of mid-stage therapies in clinical trials for obesity. While the market for new therapies is huge, the challenges involved in developing a therapy that's safe, effective and free of embarrassing side effects have been vexing for the R&D crowd.

Among the most promising therapies in the pipeline: Novo Nordisk's liraglutide, which triggered weight loss of more than 5 percent in 75 percent of Phase II volunteers; Amylin Pharmaceuticals' combo of pramlintide and metreleptin, which triggered an average weight loss of 12.7 percent in 177 Phase II volunteers; and Arena Pharmaceuticals' lorcaserin, which is going into Phase III.  

- read the article from the Wall Street Journal

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.